Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii symbols : Amgn save search
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Published: 2024-04-16 (Crawled : 00:00) - biospace.com/
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
tezspire copd
AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
Published: 2023-03-01 (Crawled : 16:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 4.08%
H: 3.06%
C: 0.89%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.56%
H: 2.63%
C: 2.53%
repatha
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 4.16%
H: 3.44%
C: -1.66%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.1%
H: 0.89%
C: 0.68%
topline positive phase 2
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
Published: 2021-10-06 (Crawled : 14:00) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 0.44%
H: 2.39%
C: -2.61%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.25%
H: 0.36%
C: -0.63%
phase 2 bone positive conference
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
Published: 2021-08-02 (Crawled : 13:15) - biospace.com/
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 5.4%
H: 2.66%
C: 1.71%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.37%
H: 0.15%
C: -0.96%
treatment phase 2 bone eb613 research osteoporosis
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.06%
H: 0.92%
C: -3.19%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -0.89%
covid phase 2 trial brukinsa
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.